<DOC>
	<DOCNO>NCT02974049</DOCNO>
	<brief_summary>The recommended treatment elimination LF sub-Saharan Africa annual mass drug administration ( MDA ) single dose Albendazole ( ALB ) plus Ivermectin ( IVM ) give least 5-7 year . However , area LF co-endemic related filarial parasite , Loa loa , co-infection L. loa represent serious barrier LF elimination IVM use LF MDA result severe reaction even death individual high microfilaria ( mf ) level L. loa . Screening heavy L. loa infection problematic . To overcome problem , monotherapy ALB possible , since drug little effect circulate mf thus would cause adverse effect people heavy L. loa infection . Moreover ALB show embryostatic embryocidal effect female adult worm result decreased mf level time natural attrition circulate mf occurs . Thus open-label , randomized clinical trial examine treatment ALB monotherapy administer twice per year period 3 year primary endpoint proportion individual total clearance mf 36 month Alere antigen test negativity ( sensitive circulating antigen test filarial infection ) . Two treatment arm include ALB two different dos , 400mg 800mg ( fix dose twice yearly ) compare standard treatment ALB ( 400 mg ) plus IVM ( 150-200 µg/kg ) administer annually . Observations ongoing clinical trial Papua New Guinea suggest single dose triple therapy ALB + IVM + DEC may highly effective sterilize adult female worm . Therefore confirm expand important preliminary observation different population , fourth arm include current clinical trial subject receive three drug . The clinical trial perform region Cote d'Ivoire onchocerciasis loiasis endemic .</brief_summary>
	<brief_title>Lymphatic Filariasis ( LF ) Ivory Coast</brief_title>
	<detailed_description>Lymphatic filariasis ( LF ) deform disable infectious disease cause elephantiasis genital deformity ( especially hydroceles ) . The infection affect 120 million people 81 country tropical subtropical region well 1 billion people risk acquire disease . LF cause Wuchereria bancrofti Brugia spp . ( B. malayi B. timori ) , nematode parasite transmit mosquito . The World Health Organization ( WHO ) develop plan LF elimination base use novel approach rapidly map endemic area 4 6 annual round MDA antifilarial medication . A recent summary WHO report 4 billion dos MDA distribute 2000 2012 . Thus , Global Program Eliminate Lymphatic Filariasis ( GPELF ) large infectious disease intervention program attempt date base MDA ( Ottesen , Hooper et al . 2008 ) . MDA work well area others . There number challenge face GPELF . These include ( among others ) inability conduct MDA program area Africa L. loa coendemic unacceptable risk Serious Adverse Events ( SAE 's ) IVM person heavy L. loa infection ( Hoerauf , Pfarr et al . 2011 ) , limited macrofilaricidal activity current MDA regimen ( especially ALB + IVM ) necessitate repeat annual round MDA ( Geary Mackenzie , Hoerauf , Pfarr et al . 2011 ) , difficulty achieve high compliance rate MDA period year ( Hoerauf , Pfarr et al . 2011 ) . It clear new ( reformulate ) drug and/or dose schedule LF MDA potential greatly improve number country successfully eliminate LF WHO target date 2020 . This especially important area Central West Africa MDA implement possible co-infection L. loa logistical financial challenge deliver annual dos IVM + ALB MDA million individual multiple year .</detailed_description>
	<mesh_term>Filariasis</mesh_term>
	<mesh_term>Elephantiasis</mesh_term>
	<mesh_term>Elephantiasis , Filarial</mesh_term>
	<mesh_term>Diethylcarbamazine</mesh_term>
	<mesh_term>Albendazole</mesh_term>
	<mesh_term>Ivermectin</mesh_term>
	<criteria>Women men 1870 year ≥50 MF/mL base Nuclepore filtration Willing give inform consent Prior treatment LF within last 5 year Pregnancy ( perform pregnancy test ) Hemoglobin &lt; 7 g/dL Permanent disability , serious medical illness prevents impedes study participation and/or comprehension AST/ALT creatinine &gt; 1.5 upper limit normal Proteinuria hematuria &gt; 3+ Skin snip positivity O. volvulus MF</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Ivermectin</keyword>
	<keyword>Albendazole</keyword>
	<keyword>Diethylcarbamazine</keyword>
</DOC>